1
|
Soengas-Gonda E, Pérez de la Fuente R, Arteche-López A, Gómez-Cano MDLÁ, Quesada-Espinosa JF, Palma Milla C, Lezana Rosales JM, Mayo de Andrés S, Sánchez-Calvín MT, Gómez-Rodríguez MJ, Sierra Tomillo O, Juarez Rufian A, Ramos Gomez P, Herrero-Forte C, Fenollar-Cortés M, Cotarelo-Pérez C, García Ron A, Pérez Rodríguez O, Oancea-Ionescu R, Moreno-García M. Expanding the Phenotypic Spectrum of Alazami Syndrome: Two Unrelated Spanish Families. Neuropediatrics 2023; 54:31-36. [PMID: 36126956 DOI: 10.1055/a-1947-8411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Alazami syndrome is a rare disorder with an autosomal recessive inheritance caused by pathogenic biallelic variants in the LARP7 gene. Clinically, it is mainly characterized by short stature, intellectual disability, and dysmorphic facial features. However, the phenotype is not yet well-defined because less than 50 cases have been described to date. Here, we report three new patients from two unrelated Spanish families who, in addition to the defined features of Alazami syndrome, also exhibit unique features that broaden the phenotypic spectrum of the syndrome. Moreover, we describe the novel frameshift variant c.690_699delins27 in the LARP7 gene, in which loss of function is a known mechanism of Alazami syndrome.
Collapse
Affiliation(s)
- Emma Soengas-Gonda
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.,Mitochondrial and Neuromuscular Disorders Group, Hospital 12 de Octubre Health Research Institute (imas12), Madrid, Spain.,UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain
| | - Rubén Pérez de la Fuente
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| | - Ana Arteche-López
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| | - María de Los Ángeles Gómez-Cano
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Pediatrics, Endocrinology Unit, 12 de Octubre University Hospital, Madrid, Spain
| | - Juan Francisco Quesada-Espinosa
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| | - Carmen Palma Milla
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| | - José Miguel Lezana Rosales
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| | - Sonia Mayo de Andrés
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| | - María Teresa Sánchez-Calvín
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| | - María José Gómez-Rodríguez
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| | | | | | | | - Clara Herrero-Forte
- Clinical Genetics, Clinical Analysis Service, Molecular Diagnostics Unit, Institute of Laboratory Medicine (UDM-IML), Clinico San Carlos University Hospital, Madrid, Spain.,San Carlos Clinical Research Institute (IdISSC), Madrid, Spain
| | - Maria Fenollar-Cortés
- Clinical Genetics, Clinical Analysis Service, Molecular Diagnostics Unit, Institute of Laboratory Medicine (UDM-IML), Clinico San Carlos University Hospital, Madrid, Spain.,San Carlos Clinical Research Institute (IdISSC), Madrid, Spain
| | - Carmen Cotarelo-Pérez
- Clinical Genetics, Clinical Analysis Service, Molecular Diagnostics Unit, Institute of Laboratory Medicine (UDM-IML), Clinico San Carlos University Hospital, Madrid, Spain.,San Carlos Clinical Research Institute (IdISSC), Madrid, Spain
| | - Adrián García Ron
- Neuropaediatrics Unit, Child and Adolescent Institute, Clinico San Carlos University Hospital, Madrid, Spain
| | | | - Raluca Oancea-Ionescu
- Clinical Genetics, Clinical Analysis Service, Molecular Diagnostics Unit, Institute of Laboratory Medicine (UDM-IML), Clinico San Carlos University Hospital, Madrid, Spain.,San Carlos Clinical Research Institute (IdISSC), Madrid, Spain
| | - Marta Moreno-García
- UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid, Spain.,Department of Genetics, 12 de Octubre University Hospital, Madrid, Spain
| |
Collapse
|
2
|
Damián A, Ionescu RO, Rodríguez de Alba M, Tamayo A, Trujillo-Tiebas MJ, Cotarelo-Pérez MC, Pérez Rodríguez O, Villaverde C, de la Fuente L, Romero R, Núñez-Moreno G, Mínguez P, Ayuso C, Cortón M. Fine Breakpoint Mapping by Genome Sequencing Reveals the First Large X Inversion Disrupting the NHS Gene in a Patient with Syndromic Cataracts. Int J Mol Sci 2021; 22:ijms222312713. [PMID: 34884523 PMCID: PMC8657747 DOI: 10.3390/ijms222312713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Revised: 11/17/2021] [Accepted: 11/19/2021] [Indexed: 11/16/2022] Open
Abstract
Inversions are structural variants that are generally balanced. However, they could lead to gene disruptions or have positional effects leading to diseases. Mutations in the NHS gene cause Nance-Horan syndrome, an X-linked disorder characterised by congenital cataracts and dental anomalies. Here, we aimed to characterise a balanced pericentric inversion X(p22q27), maternally inherited, in a child with syndromic bilateral cataracts by breakpoint mapping using whole-genome sequencing (WGS). 30× Illumina paired-end WGS was performed in the proband, and breakpoints were confirmed by Sanger sequencing. EdU assays and FISH analysis were used to assess skewed X-inactivation patterns. RNA expression of involved genes in the breakpoint boundaries was evaluated by droplet-digital PCR. We defined the breakpoint position of the inversion at Xp22.13, with a 15 bp deletion, disrupting the unusually large intron 1 of the canonical NHS isoform, and also perturbing topologically-associated domains (TADs). Moreover, a microhomology region of 5 bp was found on both sides. RNA analysis confirmed null and reduced NHS expression in the proband and his unaffected mother, respectively. In conclusion, we report the first chromosomal inversion disrupting NHS, fine-mapped by WGS. Our data expand the clinical spectrum and the pathogenic mechanisms underlying the NHS defects.
Collapse
Affiliation(s)
- Alejandra Damián
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
| | - Raluca Oancea Ionescu
- Department of Medical Genetics, University Hospital Clínico San Carlos, 28040 Madrid, Spain; (R.O.I.); (M.C.C.P.)
| | - Marta Rodríguez de Alba
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
| | - Alejandra Tamayo
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
| | - María José Trujillo-Tiebas
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
| | - María Carmen Cotarelo-Pérez
- Department of Medical Genetics, University Hospital Clínico San Carlos, 28040 Madrid, Spain; (R.O.I.); (M.C.C.P.)
| | - Olga Pérez Rodríguez
- Department of Pediatrics, University Hospital Clínico San Carlos, 28040 Madrid, Spain;
| | - Cristina Villaverde
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
| | - Lorena de la Fuente
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
- Bioinformatics Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain
| | - Raquel Romero
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
| | - Gonzalo Núñez-Moreno
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Bioinformatics Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain
| | - Pablo Mínguez
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
- Bioinformatics Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain
| | - Carmen Ayuso
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
| | - Marta Cortón
- Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; (A.D.); (M.R.d.A.); (A.T.); (M.J.T.-T); (C.V.); (L.d.l.F.); (R.R.); (G.N.-M); (P.M.); (C.A.)
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), 28290 Madrid, Spain
- Correspondence:
| |
Collapse
|
3
|
López de Lara D, Pérez Rodríguez O, Cuellar Flores I, Pedreira Masa JL, Campos-Muñoz L, Cuesta Hernández M, Ramos Amador JT. [Psychosocial assessment in transgender adolescents]. An Pediatr (Barc) 2020; 93:41-48. [PMID: 32144041 DOI: 10.1016/j.anpedi.2020.01.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 12/26/2019] [Accepted: 01/23/2020] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVES To evaluate the psychosocial status of the patients who attend a paediatric endocrinology clinic due to gender incongruity (GI), and to establish the impact on this after one-year of cross hormonal therapy (CHT). MATERIAL AND METHODS An analytical and prospective study conducted on adolescents between 14 and 18 years old with GI, and who attended the Endocrinology clinic during 2018-2019. The sample included 23 transgender cases (16 male and 7 female cases) and 30 cisgender controls. Study variables were collected at T0 (pre-treatment) and T1 (after one year of CHT) and included sociodemographic data, Utrecht test, SDQ-Cas test, family APGAR test, STAI scale-anxiety Grade, and BDI-II depression assessment test. RESULTS A significant improvement (P<.05) was found between T0 and T1 in the transgender group in terms of emotional symptoms, behaviour problems, hyperactivity symptoms, pro-social conduct, as well as in the degree of anxiety and depression measured by the SDQ-Cas test, the STAI and the BDI-II scale. There were significant differences in these scales between the transgender group and the controls at T0, however, the scores equalised at T1. The families in this sample of transgender patients provided a very favourable environment according to the scores obtained on the family APGAR scale. CONCLUSIONS The rates of anxiety, emotional and behaviour distress, depressive symptomatology, as well as the feeling of gender dysphoria of these transgender patients were similar to those of non-transsexual population of the same age after one year of CHT initiated at ages between 14-18 years old.
Collapse
Affiliation(s)
- Diego López de Lara
- Unidad de Endocrinología Infantil, Hospital Clínico San Carlos, Madrid, España.
| | | | - Isabel Cuellar Flores
- Unidad de Psicología Clínica, Servicio de Pediatría, Hospital Clínico San Carlos, Madrid, España
| | | | | | | | | |
Collapse
|